Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.3%

1 terminated out of 19 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

26%

5 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results92% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (6)
P 1 (1)
P 3 (3)
P 4 (2)

Trial Status

Completed12
Recruiting5
Active Not Recruiting1
Terminated1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT07102160RecruitingPrimary

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

NCT07455253Active Not Recruiting

Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery

NCT07439991Recruiting

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

NCT06909240Not ApplicableRecruitingPrimary

Progressive Gait Training After First-time Deep Venous Thrombosis: Clinical Effectiveness and Involved Mecanisms (The DVT-Cph RCT)

NCT07330661Not ApplicableCompletedPrimary

Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery

NCT07077954Phase 1CompletedPrimary

COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSIS

NCT06195787CompletedPrimary

Improving Emergency Department Testing for Deep Vein Thrombosis

NCT06930937Not ApplicableCompleted

To Compare and Evaluate the Oral Bioavailability of Edoxaban 60 mg Film Coated Tablet With That of Lixiana® 60 mg Filmtabletten (Film Coated Tablet) (Edoxaban) in Healthy, Adult, Human Subjects Under Fasting Conditions

NCT02798471Phase 3Completed

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT01630148Not ApplicableCompletedPrimary

Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries

NCT02156401Recruiting

VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE

NCT02342444Phase 4Recruiting

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02744092Not ApplicableCompleted

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02205294Not ApplicableCompletedPrimary

Osteopathic Treatment and Deep Vein Thrombosis (DVT)

NCT02210819CompletedPrimary

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

NCT02523937Completed

Evaluation of Soluble Fibrin in Thrombosis Exclusion

NCT03805672Phase 4TerminatedPrimary

Below Knee DVT Study

NCT02073682Phase 3Completed

Cancer Venous Thromboembolism (VTE)

NCT00986154Phase 3Completed

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Showing all 19 trials

Research Network

Activity Timeline